Overview

LOWER: Lomitapide Observational Worldwide Evaluation Registry

Status:
Recruiting

Trial end date:
2028-09-01

Target enrollment:

Participant gender:

Summary

This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.

Details

Lead Sponsor:

Aegerion Pharmaceuticals, Inc.
Amryt Pharma